Aeglea BioTherapeutics Inc.

(NASDAQ: AGLE) Trade

By |

Equities News

Company chart and information is provided by TradingView based on 15-minute-delayed data.


Profile

Aeglea BioTherapeutics Inc is a clinical-stage biotechnology company. It designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in an early clinical development stage.

Contact Information

Website: www.aegleabio.com
Email: investors@aegleabio.com
Main Phone: +1 512 942-2935
Address: 805 Las Cimas Parkway
Address 2: Suite 100
State: TX
City / Town: Austin
Country: US
Postal Code: 78746

Issuer Information

Exchange: NSD
CEO: Anthony G. Quinn
Employees: 90
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

(%)
Company data no longer available
Last Price N/A Change $ N/A Change % N/A Tick N/A
Bid N/A Bid Size N/A Ask N/A Ask Size N/A
Open N/A High N/A Low N/A Prev Close N/A
Last Trade Volume N/A 52 Wk Hi N/A 52 Wk Low N/A
Market Cap N/A Ex-Div Date N/A Div Rate N/A Yield N/A
Shares N/A EPS (TTM) N/A PE Ratio N/A Exchange N/A